Drug Profile
Recombinant erythropoietin long-acting - Shandong Kexing Bioproducts
Latest Information Update: 10 Feb 2014
Price :
$50
*
At a glance
- Originator Shandong Kexing Bioproducts Co; Unknown
- Developer Shandong Kexing Bioproducts Co
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Anaemia
Most Recent Events
- 01 Jan 2014 Investigation in Anaemia in China (Parenteral)